Developer docs
API playgroundTry for free, no card

Search company profiles

CosmosID

Full company profile

uuid0002r3o

Namestring
CosmosID
Websiteurl
cosmosid.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

CosmosID is a bioinformatics company specializing in the rapid identification of microorganisms in metagenomic samples, founded in 2007 and headquartered in Rockville, Maryland. The company builds technology that integrates multi-omics (genomics, metagenomics, and related layers) with AI and systems biology to support microbiome research, discovery, development, and clinical validation workflows. Its capabilities are described as a core component of Cmbio's Digital Biology platform, which combines multi-omics, AI, and systems biology into a unified model for microbiome innovation spanning discovery through commercialization.

CosmosID has historically operated with a small team (11–50 employees) and has raised approximately $7.2M across two funding rounds (2011 and 2016), the most recent led by Applied Value. Its leadership includes CEO Manoj Dadlani, Founder and Chairman Rita R. Colwell (a recognized figure in microbiome science), and CSO Tom Cebula. The company was profiled among 10 Maryland life science companies pioneering AI innovation, signaling reputational positioning at the intersection of microbiome research and applied AI. The company is now associated with parent Cmbio, a Denmark and US-based microbiome innovation company that has expanded through acquisitions and integrated CosmosID's capabilities into its unified platform model.

Pricing is not publicly disclosed, and no customer logos, revenue figures, or go-to-market segmentation details are available in the source data. The absence of post-2016 disclosed funding activity, combined with the documented integration into Cmbio's platform, suggests CosmosID's standalone commercial identity has been substantially subsumed into a parent-led ecosystem strategy. As a result, the unit economics, pricing model, and customer mix for CosmosID as an independent entity are not separately verifiable from available sources.

Short descriptiontext

CosmosID is a bioinformatics company specializing in rapid microorganism identification in metagenomic samples using AI-integrated multi-omics technology. Founded in 2007 in Rockville, Maryland, it serves microbiome research customers and is now integrated into parent Cmbio's Digital Biology platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
microbiome analytics software, metagenomic sequencing services, multi-omics bioinformatics, microbial identification platform, pathogen detection genomics
Industry5 codes
1Bioinformatics & Multi-omics Analysis Software
CodeHLAGAJADPrimaryYes
2Microbiome Analytics, Sequencing & Bioinformatics Platforms
CodeHLAAAFAIPrimaryNo
3Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
CodeHLAGANAIPrimaryNo
4Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
CodeHLAAAFAHPrimaryNo
5Microbiome & Metagenomics Services
CodeHLAGANAHPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Bioinformatics Software
Social media profiles3 records
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

CosmosID is a bioinformatics company that provides metagenomics and microbiome analysis technology for the rapid identification of microorganisms in metagenomic samples. Its platform combines multi-omics technologies with AI and systems biology to support discovery, development, and clinical validation workflows for microbiome research and related applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CosmosID is a metagenomics and microbiome analysis technology that has been utilized as a component within Cmbio's integrated Digital Biology platform, which combines multi-omics technologies, AI, and systems biology. CosmosID's technology contributes to microbiome discovery, development, and clinical validation workflows.

Product and service1 record
1CosmosID
CategoryBioinformatics / Microbiome Analytics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Cmbio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CosmosID was historically utilized by Cmbio as part of their integrated microbiome research platform called Digital Biology. Cmbio has expanded through acquisitions, integrating various scientific capabilities including CosmosID's multi-omics technologies into a unified model. The relationship indicates CosmosID was part of Cmbio's portfolio of entities supporting microbiome innovation from discovery to commercialization.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Ginkgo Bioworks
TypeEmerging player
Description

Synthetic biology platform with significant microbiome engineering and analytics capabilities — adjacent in organism-centric data and AI-driven biology workflows.

2DNAnexus
TypeDirect peer
Description

Cloud-based bioinformatics platform for genomic and multi-omic data analysis, comparable as a data infrastructure and analysis layer for life sciences customers.

3Illumina
TypeBroad incumbent
Description

Dominant sequencing platform vendor increasingly moving into secondary analysis and bioinformatics for microbial and metagenomic applications — overlaps at the data layer.

4Metabolon
TypeDirect peer
Description

Specialized multi-omics services provider combining metabolomics with microbiome and informatics — comparable on the multi-omics analytics model CosmosID applies.

5Second Genome
TypeEmerging player
Description

Microbiome-focused drug discovery and biomarker company using multi-omics and computational biology — a peer in applying analytics to microbiome therapeutic pipelines.

6Eagle Genomics
TypeEmerging player
Description

AI-driven multi-omics and microbiome analytics platform for R&D, offering knowledge graphs comparable to CosmosID's AI + systems biology positioning.

7Diversigen
TypeDirect peer
Description

Microbiome and metagenomics sequencing services provider offering end-to-end analytical workflows, directly comparable to CosmosID's metagenomic identification capabilities.

8Zymo Research
TypeDirect peer
Description

Provides microbiome collection devices, reagents, and bioinformatics services including metagenomic analysis — overlapping with CosmosID's core offering.

9QIAGEN
TypeBroad incumbent
Description

Major life science tools provider with a bioinformatics portfolio (including via Diversigen) — a broader incumbent competing in microbiome sample-to-insight workflows.

10Bio-Rad Laboratories
TypeBroad incumbent
Description

Diversified life science tools vendor with digital PCR, sequencing, and bioinformatics offerings touching microbiome research customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CosmosID

Bioinformatics Softwarecosmosid.com

CosmosID is a bioinformatics company specializing in rapid microorganism identification in metagenomic samples using AI-integrated multi-omics technology. Founded in 2007 in Rockville, Maryland, it serves microbiome research customers and is now integrated into parent Cmbio's Digital Biology platform.

What CosmosID does

CosmosID is a bioinformatics company specializing in the rapid identification of microorganisms in metagenomic samples, founded in 2007 and headquartered in Rockville, Maryland. The company builds technology that integrates multi-omics (genomics, metagenomics, and related layers) with AI and systems biology to support microbiome research, discovery, development, and clinical validation workflows. Its capabilities are described as a core component of Cmbio's Digital Biology platform, which combines multi-omics, AI, and systems biology into a unified model for microbiome innovation spanning discovery through commercialization.

CosmosID has historically operated with a small team (11–50 employees) and has raised approximately $7.2M across two funding rounds (2011 and 2016), the most recent led by Applied Value. Its leadership includes CEO Manoj Dadlani, Founder and Chairman Rita R. Colwell (a recognized figure in microbiome science), and CSO Tom Cebula. The company was profiled among 10 Maryland life science companies pioneering AI innovation, signaling reputational positioning at the intersection of microbiome research and applied AI. The company is now associated with parent Cmbio, a Denmark and US-based microbiome innovation company that has expanded through acquisitions and integrated CosmosID's capabilities into its unified platform model.

Pricing is not publicly disclosed, and no customer logos, revenue figures, or go-to-market segmentation details are available in the source data. The absence of post-2016 disclosed funding activity, combined with the documented integration into Cmbio's platform, suggests CosmosID's standalone commercial identity has been substantially subsumed into a parent-led ecosystem strategy. As a result, the unit economics, pricing model, and customer mix for CosmosID as an independent entity are not separately verifiable from available sources.

CosmosID firmographics

Firmographics
Name
CosmosID
Website
https://cosmosid.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
CosmosID is a bioinformatics company specializing in rapid microorganism identification in metagenomic samples using AI-integrated multi-omics technology. Founded in 2007 in Rockville, Maryland, it serves microbiome research customers and is now integrated into parent Cmbio's Digital Biology platform.
Ownership category
akta.pro rank

CosmosID industry classification

Industry
Product category
Bioinformatics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro primary industry
Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
akta.pro secondary industries
Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH), Microbiome & Metagenomics Services (HLAGANAH)

Keywords

  • Microbiome analytics software
  • Metagenomic sequencing services
  • Multi-omics bioinformatics
  • Microbial identification platform
  • Pathogen detection genomics

Where CosmosID is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Markets served

CosmosID business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

CosmosID product offering

Product offering

Core offering

CosmosID is a bioinformatics company that provides metagenomics and microbiome analysis technology for the rapid identification of microorganisms in metagenomic samples. Its platform combines multi-omics technologies with AI and systems biology to support discovery, development, and clinical validation workflows for microbiome research and related applications.

Product overview

CosmosID is a metagenomics and microbiome analysis technology that has been utilized as a component within Cmbio's integrated Digital Biology platform, which combines multi-omics technologies, AI, and systems biology. CosmosID's technology contributes to microbiome discovery, development, and clinical validation workflows.

Differentiator

Problem solved

Functional benefit

Products and services

  • CosmosID

Companies that use CosmosID

Customer profile

Ideal customer profiles3 records

CosmosID technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CosmosID partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CmbiocoreStrategic or Co-development PartnerCosmosID was historically utilized by Cmbio as part of their integrated microbiome research platform called Digital Biology. Cmbio has expanded through acquisitions, integrating various scientific capabilities including CosmosID's multi-omics technologies into a unified model. The relationship indicates CosmosID was part of Cmbio's portfolio of entities supporting microbiome innovation from discovery to commercialization.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

CosmosID competitors and assessment

Company assessment

Emerging players

  • Ginkgo Bioworks: Synthetic biology platform with significant microbiome engineering and analytics capabilities — adjacent in organism-centric data and AI-driven biology workflows.
  • Second Genome: Microbiome-focused drug discovery and biomarker company using multi-omics and computational biology — a peer in applying analytics to microbiome therapeutic pipelines.
  • Eagle Genomics: AI-driven multi-omics and microbiome analytics platform for R&D, offering knowledge graphs comparable to CosmosID's AI + systems biology positioning.

Direct peers

  • DNAnexus: Cloud-based bioinformatics platform for genomic and multi-omic data analysis, comparable as a data infrastructure and analysis layer for life sciences customers.
  • Metabolon: Specialized multi-omics services provider combining metabolomics with microbiome and informatics — comparable on the multi-omics analytics model CosmosID applies.
  • Diversigen: Microbiome and metagenomics sequencing services provider offering end-to-end analytical workflows, directly comparable to CosmosID's metagenomic identification capabilities.
  • Zymo Research: Provides microbiome collection devices, reagents, and bioinformatics services including metagenomic analysis — overlapping with CosmosID's core offering.

Broad incumbents

  • Illumina: Dominant sequencing platform vendor increasingly moving into secondary analysis and bioinformatics for microbial and metagenomic applications — overlaps at the data layer.
  • QIAGEN: Major life science tools provider with a bioinformatics portfolio (including via Diversigen) — a broader incumbent competing in microbiome sample-to-insight workflows.
  • Bio-Rad Laboratories: Diversified life science tools vendor with digital PCR, sequencing, and bioinformatics offerings touching microbiome research customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

CosmosID social profiles

Digital presence

CosmosID financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CosmosID leadership team

Management profile

Number of profiles

Profiles3 records

CosmosID funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CosmosID M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CosmosID

What does CosmosID do?

CosmosID is a bioinformatics company that provides metagenomics and microbiome analysis technology for the rapid identification of microorganisms in metagenomic samples. Its platform combines multi-omics technologies with AI and systems biology to support discovery, development, and clinical validation workflows for microbiome research and related applications.

When was CosmosID founded?

CosmosID was founded in 2007. It employs 11 to 50 people.

Where is CosmosID based?

CosmosID is headquartered in Rockville, United States, in the North America region.

Who are CosmosID's main competitors?

Emerging players on record are Ginkgo Bioworks, Second Genome and Eagle Genomics. Direct peers are DNAnexus, Metabolon, Diversigen and Zymo Research. Broad incumbents are Illumina, QIAGEN and Bio-Rad Laboratories.

Does CosmosID have an API?

No public API is recorded for CosmosID.

What industry is CosmosID in?

CosmosID's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WikipediaRita R. Colwell: Difference between revisionsThe article provides a biographical overview of Rita R. Colwell, highlighting her career as an environmental microbiologist and her tenure as the first female director of the National Science Foundation from 1998 to 2004. It details her significant research on cholera transmission and water filtration methods, as well as her role in founding the bioinformatics company CosmosID in 2008.PR NewswireCosmosID Announces Collaboration with Resilient Biotics for Advanced Microbiome Exploration of the Respiratory TractCosmosID, a microbiome analytics company headquartered in Germantown, Maryland, has announced a collaboration with Resilient Biotics to jointly explore and analyze microbiome strains colonizing respiratory tract tissues. The partnership will leverage CosmosID's next-generation sequencing services and bioinformatic capabilities to study respiratory microbiome systems across multiple animal models using Resilient Biotics' strain collection. Both companies expect this research to uncover insights that could lead to new therapeutic interventions and diagnostics for respiratory health.PR NewswireCosmosID Announces Metabolomics Services, Expands Multi-Omics CapabilitiesCosmosID announced the launch of its metabolomics services, expanding its multi-omics microbiome research capabilities by combining Liquid Chromatography-Mass Spectrometry and Gas Chromatography-Mass Spectroscopy to detect over 100,000 metabolites alongside its existing metagenomics and metatranscriptomics offerings. The service provides comprehensive metabolite profiling with relative and absolute quantitation, plus customizable panels of over 650 target metabolites tailored to client needs. CEO Manoj Dadlani stated the integration of strain-level microbiome resolution with metabolite profiling will enhance understanding of microbiome functionality and help link observations with biological mechanisms.PR NewswireNew SARS-CoV-2 Assay by CosmosID Eases Disruptions in Supply Chain for Patient Fecal Microbiota TransplantationCosmosID developed a custom SARS-CoV-2 assay test using RT-PCR technology that enables OpenBiome to screen stored fecal microbiota transplantation treatments previously held due to FDA safety alerts. The collaboration restores OpenBiome's supply chain, allowing distribution of FMT treatments to patients suffering from recurrent C. difficile infection across the US. The test covers treatments manufactured after December 2019, enabling thousands of patients who have exhausted other treatment options to access this therapy.PR NewswireCosmosID Launches Accurate and Easy Functional Microbiome Analysis with New Software Platform, CosmosID-HUB: MicrobiomeCosmosID has launched a new software platform called CosmosID-HUB: Microbiome to enhance functional microbiome analysis by combining taxonomic profiling and functional characterization. The platform features tools for easier data analysis and improved processing speeds, aimed at researchers in the field. This launch supports CosmosID's mission to make microbiome analysis more accessible and efficient for various applications.PR NewswireSandwalk BioVentures and CosmosID Launch Joint GRAS Genomic Reporting ServiceSandwalk BioVentures and CosmosID launched a joint Generally-Recognized As Safe (GRAS) genomic reporting service for the probiotics market in the USA. The turnkey solution combines CosmosID's microbial genomics infrastructure with Sandwalk's regulatory expertise to help developers accelerate time to market by meeting FDA standards.PR NewswireMicrobiome Labs Taps CosmosID for Co-Development of BiomeFx Functional Gut Microbiome TestMicrobiome Labs and CosmosID have co-developed BiomeFx, a gut microbiome stool test that utilizes CosmosID's bioinformatics software and laboratory services for sequencing and analysis. The test provides detailed insights into gut microbiota composition and metabolic potential, currently serving healthcare practitioners in the United States. Both companies plan to expand the platform by adding SARS-CoV-2 detection capabilities in a future phase.PR NewswireH2OBiome Wastewater COVID-19 Testing Service Launches Across the United StatesCosmosID has launched H2Obiome, a wastewater testing service that detects SARS-CoV-2 in sewage to provide early warning of COVID-19 community outbreaks approximately one to two weeks before recorded cases. The service utilizes qRT-PCR technology, costs $300 per sample, and is being used by universities and municipalities in Florida, California, Ohio, Maryland, and across the US. CosmosID is collaborating with the Maryland Department of Environment and Frederick County Department of Health to monitor COVID-19 virus in wastewater treatment plants as part of this initiative.PR NewswireProDigest and CosmosID Announce a Winner for the 'Gut Microbiome Therapeutic Innovation' ChallengeThe El Aidy lab from the University of Groningen has been selected as the winner of the Gut Microbiome Therapeutic Innovation challenge organized by ProDigest and CosmosID. Their winning research proposal will investigate how anti-Parkinson's Disease medication affects gut bacterial composition and microbial activity using ProDigest's SHIME® in vitro platform combined with CosmosID's microbiome analysis technology. The study aims to advance understanding of the gut-brain axis and pharmacomicrobiomics, examining how gut microbes impact drug absorption and gastrointestinal side effects.PR NewswireProDigest and CosmosID Launch the 'Gut Microbiome Therapeutic Innovation' ChallengeProDigest and CosmosID announced the launch of the 'Gut Microbiome Therapeutic Innovation' challenge, a scientific competition where the winning abstract will receive a pre-clinical gastrointestinal study using ProDigest's SHIME® in vitro simulator combined with CosmosID's microbiome analysis platform. The challenge aims to advance understanding of microbiome-based therapeutics and their effects on gut microbiota activity and composition. Abstract submissions open February 5, 2020 and close March 31, 2020, with winners selected based on research creativity, scientific impact, and innovation.